WHY IT MATTERS: Patients who have not found adequate relief from CBD or THC-based products may soon have access to better-studied CBG formulations targeting anxiety and cognitive symptoms, but those conversations with a clinician should happen before swapping or adding products. CLINICAL OVERVIEW: Cannabigerol (CBG) and its acidic precursor cannabigerolic acid (CBGA) are gaining serious scientific attention as researchers examine their potential roles in anxiety reduction, memory enhancement, and anti-cancer activity. CBGA is often called the “mother of cannabinoids” because it serves as the biosynthetic precursor from which THC, CBD, and CBC are all derived, making it a foundational compound in the cannabis plant’s chemistry.